Opportunity Information: Apply for PAR 23 180
The Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) funding opportunity (PAR 23-180) is a National Institutes of Health (NIH) discretionary grant program designed to move forward the development of new, innovative multipurpose prevention technologies (MPTs). The central goal is to support products that can address more than one sexual and reproductive health need at the same time, with a strong emphasis on prevention approaches that are practical for real-world use. The NOFO highlights three broad product use-cases it wants to advance: on-demand methods (used around the time of sex), event-driven methods (timed to exposure or specific periods of risk), and long-acting methods, including both systemic options (that work throughout the body) and non-systemic options (that work locally, such as in the genital tract).
A key scientific focus of this program is MPT development that prevents HIV infection and pregnancy together (including both hormonal and non-hormonal pregnancy prevention approaches). It also supports products aimed at preventing sexually transmitted infections (STIs) and pregnancy, preventing multiple non-HIV STIs, and preventing HIV/STIs in combination. Importantly, the NOFO is inclusive in the populations it intends to serve: it explicitly includes cisgender and transgender males and females of all ages, signaling interest in technologies that can be adapted to different anatomies, life stages, and user needs.
On the research and development side, the opportunity supports a wide range of preclinical and clinical-enabling work that is typical for advancing biomedical prevention products toward human use and, where appropriate, through clinical evaluation. Proposed projects may include pharmacokinetic (PK) studies (how a drug is absorbed, distributed, metabolized, and eliminated), pharmacodynamic (PD) studies (what the drug does in the body and how it produces its effects), safety assessments, and drug-drug interaction (DDI) studies, which are especially relevant for combination products or for users who may be taking other medications. The NOFO also emphasizes drug development and formulation science, including work supported by animal model testing, reflecting the reality that MPT success often depends not only on the active ingredients but also on delivery systems and dosage forms that are stable, acceptable, and effective.
Beyond laboratory and pharmacology work, the NOFO places real weight on behavioral and user-centered research. It supports biobehavioral and behavioral/social studies to identify product characteristics that users actually want and will stick with. That includes rheological and biophysical factors such as how a product looks and feels, perceptions of effectiveness and safety, and preferences around duration of action. The underlying idea is that uptake and consistent use are just as critical as biological efficacy, and that design choices informed by end users can improve adoption, adherence, and overall public health impact.
This is an R01 mechanism with clinical trial optional language, meaning applicants can propose projects that do or do not include a clinical trial, depending on what stage the MPT is at and what evidence is needed next. The NOFO is positioned to fund continued development rather than only early discovery, so competitive applications typically align a product concept with a clear development plan, appropriate preclinical and/or clinical-enabling studies, and measurable milestones that reduce technical risk and move the technology toward readiness for later-stage trials or implementation pathways.
Eligibility is broad and includes many types of domestic U.S. applicants such as state, county, city/township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses. The NOFO also calls out additional eligible applicant categories, reflecting an interest in partnerships and a diverse applicant pool, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non-U.S. entities (foreign organizations), among others.
Administrative details included in the source data indicate the funding opportunity title is Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional), the opportunity number is PAR 23-180, and the sponsoring agency is the National Institutes of Health. The activity category is Health, Income Security and Social Services, and the associated CFDA numbers are 93.242, 93.855, and 93.865. The original closing date listed is 2024-12-07, and the opportunity record creation date is 2023-05-09. The award ceiling and expected awards fields were not populated in the provided source, so applicants would typically look to the full NOFO text and NIH institute/center guidance for budget expectations and any program-specific funding targets.Apply for PAR 23 180
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.855, 93.865.
- This funding opportunity was created on 2023-05-09.
- Applicants must submit their applications by 2024-12-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: FY2023 Historic Preservation Fund- African American Civil Rights- Preservation Grants
Previous opportunity: BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 180
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 180) also looked into and applied for these:
| Funding Opportunity |
|---|
| Specialized Centers for Research on Health Disparities in Uterine Leiomyoma (SCHDUL) (P50 Clinical Trial Not Allowed) Apply for RFA HD 24 005 Funding Number: RFA HD 24 005 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed) Apply for PAR 23 193 Funding Number: PAR 23 193 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Prevention and Treatment through a Comprehensive Care Continuum for HIV-affected Adolescents in Resource Constrained Settings Implementation Science Network (PATCH-IN) Implementation Science Coordinating Center (UM2 Clinical Trial Optional) Apply for RFA HD 24 009 Funding Number: RFA HD 24 009 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,250,000 |
| National Centers for Translational Research in Reproduction and Infertility (NCTRI) (P50 Clinical Trial Optional) Apply for RFA HD 24 010 Funding Number: RFA HD 24 010 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,100,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) Apply for RFA MH 24 160 Funding Number: RFA MH 24 160 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional) Apply for RFA MH 24 161 Funding Number: RFA MH 24 161 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Diagnostic Centers of Excellence for the Undiagnosed Diseases Network (U01 Clinical Trial Not Allowed) Apply for PAR 23 289 Funding Number: PAR 23 289 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $500,000 |
| BRAIN Initiative: Research on the Ethical Implications of Advancements in Neurotechnology and Brain Science (R01 Clinical Trial Optional) Apply for RFA MH 24 190 Funding Number: RFA MH 24 190 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Opportunities for HIV Cure Strategies at the Time of ART Initiation (R21 Clinical Trial Not Allowed) Apply for PAR 23 296 Funding Number: PAR 23 296 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R21 Clinical Trial Optional) Apply for RFA MH 24 331 Funding Number: RFA MH 24 331 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| Opportunities for HIV Cure Strategies at the Time of ART Initiation (R01 Clinical Trial Not Allowed) Apply for PAR 23 297 Funding Number: PAR 23 297 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R01 Clinical Trial Optional) Apply for RFA MH 24 330 Funding Number: RFA MH 24 330 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Senator Paul D. Wellstone Muscular Dystrophy Specialized Research Centers (MDSRC) (P50 Clinical Trial Optional) Apply for RFA NS 23 032 Funding Number: RFA NS 23 032 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $1,000,000 |
| Leveraging Extant Data to Understand Developmental Trajectories of Late Talking Children (R21 Clinical Trial Not Allowed) Apply for PAR 24 045 Funding Number: PAR 24 045 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| HEAL Initiative: Limited Competition: Data Coordinating Center for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (U24 Clinical Trial Not Allowed) Apply for RFA HD 24 015 Funding Number: RFA HD 24 015 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Information and Practice Needs Relevant to Late Talking Children (R21 Clinical Trial Not Allowed) Apply for PAR 24 046 Funding Number: PAR 24 046 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $275,000 |
| HEAL Initiative: Limited Competition: Clinical Centers for Completion of the Outcomes of Babies with Opioid Exposure (OBOE) Study (UG1 Clinical Trial Not Allowed) Apply for RFA HD 24 014 Funding Number: RFA HD 24 014 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $100,000 |
| Down Syndrome Cohort Research Sites (DS-CRS) for the Down Syndrome Cohort Study Program (DS-CDP) across the lifespan for the INCLUDE Project (U01 Clinical Trial Not Allowed) Apply for RFA OD 24 003 Funding Number: RFA OD 24 003 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
| Long-Acting Drug Delivery Systems for ART Optimization in Children Living with HIV-1 II (LADDS II) (R61/R33 Clinical Trial Not Allowed) Apply for RFA AI 23 061 Funding Number: RFA AI 23 061 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $850,000 |
| Development of Novel Nonsteroidal Contraceptive Methods (R61/R33 - Clinical Trial Not Allowed) Apply for RFA HD 25 008 Funding Number: RFA HD 25 008 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $300,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 180", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.